Literature DB >> 15645125

Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin.

Mélanie Bérubé1, Mariève Talbot, Charles Collin, Carine Paquet-Bouchard, Lucie Germain, Sylvain L Guérin, Eric Petitclerc.   

Abstract

Uveal melanoma is the most frequent primary intraocular tumor in the adult population. This malignancy has a high mortality rate and responds poorly to existing chemotherapy. Recently, the tumor environment has been found to exert a profound influence on drug response through cell interaction with components from the extracellular matrix (ECM). In the present study, we investigated whether individual components from the ECM may affect cell survival and/or cell death induced by the cytotoxic agent cisplatin on the SP6.5 uveal melanoma cell line. Tumor cells were shown by immunofluorescence analyses to be surrounded by the ECM proteins fibronectin (FN), type IV collagen (CIV) and laminin (LM), both at the primary and metastatic sites. Binding of SP6.5 cells to FN, LM and CIV is primarily dictated by the expression of membrane bound integrins from the beta1 family as revealed by cell adhesion assays conducted on ECM-coated culture plates. Analysis of cell death by flow cytometry demonstrated that culturing SP6.5 cells in the presence of FN, CIV and LM, substantially reduced the percentage of cells undergoing apoptosis after cisplatin treatment when compared with those seeded on a non-permissive matrix. These results suggest that adhesion of the SP6.5 uveal melanoma cells to the ECM proteins FN, CIV and LM might therefore confer resistance to the chemotherapeutic agent cisplatin. The cellular resistance induced by the ECM proteins toward cisplatin could explain in part the local recurrence of metastasis derived from uveal melanoma often observed clinically after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15645125

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Fibroblasts contribute to melanoma tumor growth and drug resistance.

Authors:  Edward H Flach; Vito W Rebecca; Meenhard Herlyn; Keiran S M Smalley; Alexander R A Anderson
Journal:  Mol Pharm       Date:  2011-11-08       Impact factor: 4.939

Review 2.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

3.  3D collagen type I matrix inhibits the antimigratory effect of doxorubicin.

Authors:  Emilie Millerot-Serrurot; Marie Guilbert; Nicolas Fourré; Wojciech Witkowski; Georges Said; Laurence Van Gulick; Christine Terryn; Jean-Marie Zahm; Roselyne Garnotel; Pierre Jeannesson
Journal:  Cancer Cell Int       Date:  2010-08-13       Impact factor: 5.722

4.  Transcriptional profiling of human uveal melanoma from cell lines to intraocular tumors to metastasis.

Authors:  Jean-Claude Marshall; Andre Nantel; Paula Blanco; Josee Ash; Stephanie R Cruess; Miguel N Burnier
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

5.  3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.

Authors:  Sharath Gangadhara; Chris Smith; Peter Barrett-Lee; Stephen Hiscox
Journal:  BMC Cancer       Date:  2016-06-01       Impact factor: 4.430

Review 6.  Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?

Authors:  Leonardo Marques da Fonseca; Vanessa Amil da Silva; Leonardo Freire-de-Lima; José Osvaldo Previato; Lucia Mendonça-Previato; Márcia Alves Marques Capella
Journal:  Front Oncol       Date:  2016-06-22       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.